BPC-157 is a prescription therapy used for recovery and tissue support.

Patients seeking support for recovery and tissue support may qualify after evaluation by a licensed provider.

Yes. Pentadeca Arginate (BPC-157) is a compounded prescription peptide dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, written informed consent, and full medical intake are required before dispensing to confirm candidacy, establish an individualized protocol, and ensure the patient understands the off-label nature of this therapy.

Side effects with PDA are generally mild and consistent with peptide therapies in this class. These include injection site reactions (mild redness, swelling, or transient discomfort), transient GI changes including nausea or altered bowel habits, occasional headache or mild dizziness, and temporary fatigue or increased soreness at the targeted tissue during the initial treatment phase. Serious adverse effects have not been documented in available clinical reports at therapeutic doses. Contact your provider immediately if you experience persistent injection site reactions, signs of systemic allergic response, or any unusual symptoms.

PDA is not appropriate for patients with active malignancy or a history of malignancy without thorough oncological evaluation, as its angiogenic properties raise a theoretical concern regarding tumor vascular supply. Patients who are pregnant or breastfeeding should not use this compound, as safety data is absent. Those with active autoimmune conditions or on immunosuppressive therapy require individualized provider review. PDA has not been studied in patients under 18.

Formal interaction studies have not been conducted. Patients on anticoagulants or antiplatelet agents (warfarin, heparin) should discuss concomitant use with their provider, as PDA's nitric oxide-mediated vasodilatory effects may have additive effects on vascular tone and platelet function. Patients on immunosuppressants require individualized evaluation due to PDA's immune-modulating activity. NSAIDs used concurrently may blunt the natural inflammatory phases that PDA is intended to support; providers may prefer to minimize NSAID use during therapy. Always provide a complete medication list before beginning treatment.

Patients with any malignancy history must not use PDA without thorough oncological and provider review. Those with autoimmune conditions, cardiovascular disease, significant renal or hepatic impairment, or coagulation disorders require individualized assessment. Long-term human safety data is not established, and all clinical use is off-label. Your provider requires a complete medical history before prescribing and will evaluate whether PDA is appropriate given your specific clinical picture.